The challenge
Our client needed to understand molecular diagnostic testing growth opportunities for a new biomarker in oncology. They wanted to understand the current market landscape, identify potential leverage points that would maximise use of the biomarker testing in a particular tumour and determine the appropriate stakeholders who are involved in the biomarker evaluation process.
The challenge
Our client needed to understand molecular diagnostic testing growth opportunities for a new biomarker in oncology. They wanted to understand the current market landscape, identify potential leverage points that would maximise use of the biomarker testing in a particular tumour and determine the appropriate stakeholders who are involved in the biomarker evaluation process.
Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet. Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat.
The solution
We conducted 104 qualitative face-to-face and telephone interviews with a range of different stakeholders; Oncologists, Surgeons, Radiologists and Pathologists in Canada, France, Germany, Italy, Japan, Spain, UK and US. 360°feedback on the process and the involvement of individual HCP types was gleaned using a highly explorative discussion around the processes and decision points involved. From this, decision trees were developed and opportunities and threats to testing were identified.
Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet. Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat.
The outputs
We provided our client with conclusions and recommendations based on biopsy and tissue availability, testing logistics and reactions to our client’s new biomarker assay profile. From our analysis we successfully provided key insights regarding the market landscape of molecular diagnostic testing whilst further offering advice regarding next steps and opportunities for our client’s biomarker.
Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet. Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat.